JPMorgan has issued a research report stating that China Life Insurance Company Limited (ASX: 02628) recorded a net loss of RMB 45 billion in the third quarter, primarily due to volatility in financial markets. Given that peers also experienced similar fluctuations in their earnings performance, the bank believes investors are unlikely to be too surprised by this result. JPMorgan maintains its "Overweight" rating and a target price of HK$40.
The bank noted that China Life's new business value rose 13% year-on-year in the first three quarters. As of the end of September, its core solvency ratio stood at 156%, far above the 50% minimum requirement. Management has greater flexibility regarding the final dividend proposal, and the current dividend yield of approximately 5% may have room for upside. The company already disclosed in its interim results that core earnings, excluding short-term stock market fluctuations, grew 13% year-on-year. JPMorgan expects investor focus to gradually shift toward cash profit generation capability.
The bank also noted that China Life's share price has fallen 24% year-to-date. It expects a muted market reaction to the third-quarter results, as solid new business value growth should largely offset negative sentiment arising from accounting earnings volatility.
Comments